Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Neoplasm Metastasis 2Urogenital Neoplasms 1Solitary Fibrous Tumors 1Sarcoma 1Prostatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Doxorubicin 26pembrolizumab 24Radiotherapy 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17Specimen Handling 14Nivolumab 14Gemcitabine 13Ifosfamide 12Surgical Procedures, Operative 11Biopsy 11Radiation 10X-Rays 8Temozolomide 8Ipilimumab 8pazopanib 7fludarabine 7cabozantinib 7Irinotecan 7tazemetostat 6liposomal doxorubicin 6Trabectedin 6Surveys and Questionnaires 6Phantoms, Imaging 6Blood Specimen Collection 6olaparib 5eribulin 5atezolizumab 5anlotinib 5Vincristine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Suspensions × 1 year × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡